Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2024 10:16 ET | Source: Spherix Global Insights

Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics

EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s...
October 06, 2023 06:08 ET | Source: Research and Markets

Addressing Unmet Needs: The SLE Market Grows as Research and Development Flourish

Dublin, Oct. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with...
October 04, 2023 03:00 ET | Source: Spherix Global Insights

In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In

Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
June 29, 2022 06:48 ET | Source: Research and Markets

Global Systemic Lupus Erythematosus (SLE) Market Report 2022-2026: Featuring Pfizer, AstraZeneca, GlaxoSmithKline and Others

Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with...
November 02, 2009 00:01 ET | Source: Human Genome Sciences

Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus

ROCKVILLE, MD and LONDON--(Marketwire - November 2, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary...
July 23, 2009 10:04 ET | Source: Cutting Edge Information

Benlysta Shatters Market Expectations and Upholds Cutting Edge Information's Forecast

RESEARCH TRIANGLE PARK, NC--(Marketwire - July 23, 2009) - Benlysta, an experimental treatment for lupus, recently surprised many industry observers with positive clinical news. On Monday, shares...
July 20, 2009 00:01 ET | Source: Human Genome Sciences, Inc.

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

ROCKVILLE, MD and LONDON--(Marketwire - July 20, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab, formerly...